106 related articles for article (PubMed ID: 15591113)
1. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
[TBL] [Abstract][Full Text] [Related]
2. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
Lu X; Chen J; Sasmono RT; Hsi ED; Sarosiek KA; Tiganis T; Lossos IS
Mol Cell Biol; 2007 Mar; 27(6):2166-79. PubMed ID: 17210636
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.
Sarosiek KA; Nechushtan H; Lu X; Rosenblatt JD; Lossos IS
Br J Haematol; 2009 Nov; 147(3):308-18. PubMed ID: 19694722
[TBL] [Abstract][Full Text] [Related]
4. The biology of human lymphoid malignancies revealed by gene expression profiling.
Staudt LM; Dave S
Adv Immunol; 2005; 87():163-208. PubMed ID: 16102574
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
[TBL] [Abstract][Full Text] [Related]
6. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
Barton S; Hawkes EA; Wotherspoon A; Cunningham D
Oncologist; 2012; 17(12):1562-73. PubMed ID: 23086691
[TBL] [Abstract][Full Text] [Related]
7. Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.
Raboso-Gallego J; Casado-García A; Jiang X; Isidro-Hernández M; Gentles AJ; Zhao S; Natkunam Y; Blanco O; Domínguez V; Pintado B; Alonso-López D; De Las Rivas J; Vicente-Dueñas C; Lossos IS; Sanchez-Garcia I
Blood; 2021 Apr; 137(13):1741-1753. PubMed ID: 33024996
[TBL] [Abstract][Full Text] [Related]
8. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
[TBL] [Abstract][Full Text] [Related]
9. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.
Ricker E; Verma A; Marullo R; Gupta S; Ye C; Pannellini T; Manni M; Tam W; Inghirami G; Elemento O; Cerchietti L; Pernis AB
Sci Rep; 2020 Aug; 10(1):13094. PubMed ID: 32753663
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma.
Bewicke-Copley F; Korfi K; Araf S; Hodkinson B; Kumar E; Cummin T; Ashton-Key M; Barrans S; van Hoppe S; Burton C; Elshiekh M; Rule S; Crosbie N; Clear A; Calaminici M; Runge H; Hills RK; Scott DW; Rimsza LM; Menon G; Sha C; Davies JR; Nagano A; Davies A; Painter D; Smith A; Gribben J; Naresh KN; Westhead DR; Okosun J; Steele A; Hodson DJ; Balasubramanian S; Johnson P; Wang J; Fitzgibbon J
Blood Adv; 2023 Mar; 7(5):845-855. PubMed ID: 35947123
[TBL] [Abstract][Full Text] [Related]
11. STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment.
Benoit A; Abraham MJ; Li S; Kim J; Estrada-Tejedor R; Bakadlag R; Subramaniam N; Makhani K; Guilbert C; Tu R; Salaciak M; Klein KO; Coyle KM; Hilton LK; Santiago R; Dmitrienko S; Assouline S; Morin RD; Del Rincon SV; Johnson NA; Mann KK
Int J Hematol; 2024 Mar; 119(3):275-290. PubMed ID: 38285120
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
Polo JM; Juszczynski P; Monti S; Cerchietti L; Ye K; Greally JM; Shipp M; Melnick A
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3207-12. PubMed ID: 17360630
[TBL] [Abstract][Full Text] [Related]
13. Automatic subtyping of Diffuse Large B-cell Lymphomas (DLBCL): Raman-based genetic and metabolic classification.
Dawiec P; Leszczenko P; Nowakowska AM; Laskowska P; Szydłowski M; Juszczyński P; Baranska M; Mrówka P; Majzner K
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Mar; 309():123795. PubMed ID: 38184880
[TBL] [Abstract][Full Text] [Related]
14. Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.
Scheich S; Chen J; Liu J; Schnütgen F; Enssle JC; Ceribelli M; Thomas CJ; Choi J; Morris V; Hsiao T; Nguyen H; Wang B; Bolomsky A; Phelan JD; Corcoran S; Urlaub H; Young RM; Häupl B; Wright GW; Huang DW; Ji Y; Yu X; Xu W; Yang Y; Zhao H; Muppidi J; Pan KT; Oellerich T; Staudt LM
Cancer Discov; 2023 Aug; 13(8):1862-1883. PubMed ID: 37141112
[TBL] [Abstract][Full Text] [Related]
15. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.
Care MA; Cocco M; Laye JP; Barnes N; Huang Y; Wang M; Barrans S; Du M; Jack A; Westhead DR; Doody GM; Tooze RM
Nucleic Acids Res; 2014 Jul; 42(12):7591-610. PubMed ID: 24875472
[TBL] [Abstract][Full Text] [Related]
16. The altered metabolic pathways of diffuse large B-cell lymphoma not otherwise specified.
Rodrigues-Fernandes CI; Martins-Chaves RR; Vitório JG; Duarte-Andrade FF; Pereira TDSF; Soares CD; Moreira VR; Lebron YAR; Santos LVS; Lange LC; Canuto GAB; Gomes CC; de Macedo AN; Pontes HAR; Burbano RMR; Martins MD; Pires FR; Mesquita RA; Gomez RS; Santos-Silva AR; Lopes MA; Vargas PA; Fonseca FP
Leuk Lymphoma; 2023; 64(11):1771-1781. PubMed ID: 37462418
[TBL] [Abstract][Full Text] [Related]
17. High density of FOXP3 predicts better prognosis in germinal and non-germinal centre diffuse large B-cell lymphoma.
Ahmed AM; Abdel-Hakeem SS; Amine MAF; Yassin EH; Badary FAM
Int J Exp Pathol; 2023 Jun; 104(3):128-139. PubMed ID: 36974470
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma.
Zhu F; Hwang B; Miyamoto S; Rui L
Mol Cancer Res; 2017 Mar; 15(3):348-357. PubMed ID: 28031410
[TBL] [Abstract][Full Text] [Related]
19. Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.
Uhl B; Prochazka KT; Pansy K; Wenzl K; Strobl J; Baumgartner C; Szmyra MM; Waha JE; Wolf A; Tomazic PV; Steinbauer E; Steinwender M; Friedl S; Weniger M; Küppers R; Pichler M; Greinix HT; Stary G; Ramsay AG; Apollonio B; Feichtinger J; Beham-Schmid C; Neumeister P; Deutsch AJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887224
[TBL] [Abstract][Full Text] [Related]
20. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.
Urata T; Naoi Y; Jiang A; Boyle M; Sunami K; Imai T; Nawa Y; Hiramatsu Y; Yamamoto K; Fujii S; Yoshida I; Yano T; Chijimatsu R; Murakami H; Ikeuchi K; Kobayashi H; Tani K; Ujiie H; Inoue H; Tomida S; Yamamoto A; Kondo T; Fujiwara H; Asada N; Nishimori H; Fujii K; Fujii N; Matsuoka KI; Sawada K; Momose S; Tamaru JI; Nishikori A; Sato Y; Yoshino T; Maeda Y; Scott DW; Ennishi D
Blood Adv; 2023 Dec; 7(24):7459-7470. PubMed ID: 37552496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
